Showing results (21-30 of 211) with videos related to
Sort By:
Pageof 22
Neurochemistry International|December 1, 1992
Striatal quinolinic acid lesions increase [3H]WIN 35,428 binding to the dopamine transporterD R Gehlert, D D SchoeppEuropean Journal of Pharmacology|February 22, 1996
Differentiation of group 2 and group 3 metabotropic glutamate receptor cAMP responses in the rat hippocampusR A Wright, D D SchoeppBiochemical Pharmacology|August 1, 1985
Comparison of postnatal changes in alpha 1-adrenoceptor binding and adrenergic stimulation of phosphoinositide hydrolysis in rat cerebral cortexD D Schoepp, C O RutledgeJournal of Neurochemistry|June 1, 1985
Further studies on the nature of postsynaptic dopamine uptake and metabolism in rat striatum: sodium dependency and investigation of a possible role for carrier-mediated uptake into serotonin neuronsD D Schoepp, A J AzzaroNeurochemistry International|May 28, 2010
In vivo 2-amino-3-phosphonopropionic acid administration to neonatal rats selectively inhibits metabotropic excitatory amino acid receptors ex vivo in brain slicesD D Schoepp, B G JohnsonJournal of Neurochemistry|August 1, 1981
Alteration of dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibitionD D Schoepp, A J AzzaroThe Journal of Pharmacology and Experimental Therapeutics|September 22, 1999
The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in ratsJ Cartmell, J A Monn, D D SchoeppEuropean Journal of Pharmacology|September 16, 2000
The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearingJ Cartmell, J A Monn, D D SchoeppPsychopharmacology|August 6, 2000
Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapineJ Cartmell, J A Monn, D D SchoeppNaunyn-Schmiedeberg'S Archives of Pharmacology|January 29, 2000
Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268J Cartmell, J A Monn, D D SchoeppPageof 22